

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 7, 2025

FITC anti-mouse CD279 (PD-1)

RRID:AB_10680238

Type: Antibody

Proper Citation

(BioLegend Cat# 135214, RRID:AB_10680238)

Antibody Information

URL: http://antibodyregistry.org/AB_10680238

Proper Citation: (BioLegend Cat# 135214, RRID:AB_10680238)

Target Antigen: CD279

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-mouse CD279 (PD-1)

Description: This monoclonal targets CD279

Target Organism: mouse

Clone ID: Clone 29F.1A12

Antibody ID: AB_10680238

Vendor: BioLegend

Catalog Number: 135214

Alternative Catalog Numbers: 135213

Record Creation Time: 20231110T070356+0000

Record Last Update: 20241115T023816+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-mouse CD279 (PD-1).

No alerts have been found for FITC anti-mouse CD279 (PD-1).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Bauer KC, et al. (2024) The Gut Microbiome Controls Liver Tumors via the Vagus Nerve. bioRxiv : the preprint server for biology.

Ma R, et al. (2024) Vimentin modulates regulatory T cell receptor-ligand interactions at distal pole complex, leading to dysregulated host response to viral pneumonia. Cell reports, 43(12), 115056.

Cui L, et al. (2024) Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer. Cancer research.

Sprooten J, et al. (2024) Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells. Cell reports. Medicine, 5(1), 101377.

Ma S, et al. (2024) Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity. Cancer cell.

Jin G, et al. (2024) A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice. Nature immunology, 25(6), 1059.

Ben Nasr M, et al. (2024) Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule. Cell metabolism, 36(6), 1302.

Nagaraju GP, et al. (2024) Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Cell reports. Medicine, 101881.

Wang X, et al. (2024) Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy. Cell reports, 43(2), 113712.

Chang YW, et al. (2023) A CSF-1R-blocking antibody/IL-10 fusion protein increases anti-

tumor immunity by effectuating tumor-resident CD8⁺ T cells. *Cell reports. Medicine*, 4(8), 101154.

Olivera I, et al. (2023) mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy. *Cell reports. Medicine*, 4(3), 100978.

Nava Lauson CB, et al. (2023) Linoleic acid potentiates CD8⁺ T cell metabolic fitness and antitumor immunity. *Cell metabolism*, 35(4), 633.

Muñoz-Ruiz M, et al. (2023) IFN- γ -dependent interactions between tissue-intrinsic $\gamma\gamma$ T cells and tissue-infiltrating CD8 T cells limit allergic contact dermatitis. *The Journal of allergy and clinical immunology*, 152(6), 1520.

Klement JD, et al. (2023) Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment. *Cancer cell*, 41(3), 620.

Reticker-Flynn NE, et al. (2022) Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. *Cell*, 185(11), 1924.

Liu H, et al. (2022) KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. *Cancer immunology research*, 10(8), 1028.

Dubrot J, et al. (2021) In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma. *Immunity*, 54(3), 571.

Zhao H, et al. (2021) Genome-wide fitness gene identification reveals Roquin as a potent suppressor of CD8 T cell expansion and anti-tumor immunity. *Cell reports*, 37(10), 110083.

Tartey S, et al. (2021) A MyD88/IL1R Axis Regulates PD-1 Expression on Tumor-Associated Macrophages and Sustains Their Immunosuppressive Function in Melanoma. *Cancer research*, 81(9), 2358.

Hong JP, et al. (2020) An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses. *Cell reports. Medicine*, 1(3).